Betta Pharmaceuticals Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Public, Subsidiary
- Established
- 2003-01-07
- Employees
- 1.9K
- Market Cap
- -
- Website
- https://www.bettapharma.com
Clinical Trials
72
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (72 trials with phase data)• Click on a phase to view related trials
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06885840
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Dongguan People's Hospital, Dongguan, Guangdong, China
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation
- Interventions
- Drug: Dose-Escalation (Phase Ia) CFT8919 capsuleDrug: Dose-Expansion (Phase Ib) CFT8919 capsuleDrug: Cohort-Expansion (Phase Ic) CFT8919 capsule
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT06641609
- Locations
- 🇨🇳
浙江省杭州市拱墅区半山东路1号的英文翻译为： No. 1 Banshan East Road, Gongshu District, Hangzhou, Zhejiang Province, China, Hangzhou, Zhejiang, China
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06492525
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
- Conditions
- Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant Therapy
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 570
- Registration Number
- NCT06041776
- Locations
- 🇨🇳
Peking University International Hospital, Beijing, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, China
🇨🇳Shanghai chest hospital, Shanghai, China
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
- Conditions
- Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 172
- Registration Number
- NCT06015568
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Hunan cancer hospital, Changsha, Hunan, China
🇨🇳Shanghai chest hospital, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
Angel Pharmaceuticals Receives China IND Approval for Soquelitinib Atopic Dermatitis Trial
Angel Pharmaceuticals received IND approval from China's NMPA to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis treatment.
C4 Therapeutics Announces 2025 Milestones for Oncology-Focused Degrader Medicines
• C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma. • CFT1946, targeting BRAF V600 mutations in solid tumors, is progressing through Phase 1, with data readouts anticipated in the second half of 2025. • Phase 1 data from CFT8919, aimed at EGFR L858R-mutated non-small cell lung cancer, will inform future development plans outside of China. • C4 Therapeutics' cash runway is projected to fund operations into 2027, supporting ongoing research and clinical programs.
EyePoint's DURAVYU Shows Promise in Phase 2 DME Trial
EyePoint Pharmaceuticals reported positive interim results from its Phase 2 VERONA trial of DURAVYU for diabetic macular edema (DME).